Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 15, 986 - 987 (2009)
doi:10.1038/nm0909-986
Swine flu agitates the adjuvant debate
Charlotte Schubert1
- Washington DC
US regulatory agencies will face a big decision, as early as this fall, as to whether to approve the use of adjuvants for pandemic H1N1 flu vaccine on an emergency basis.Adjuvants used in some seasonal flu vaccines in Europe have the potential to boost the effectiveness of pandemic H1N1 vaccine and also substantially reduce dosage—thereby stretching supplies.
To read this story in full you will need to login or make a payment (see right).
